Obstructive Sleep Apnea A Respiratory Syndrome With Protean Cardiovascular Manifestations⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Wilcox, Ian & Semsarian, Christopher
O
A
P
I
C
S
O
s
n
d
a
O
r
a
a
u
t
c
e
s
a
p
e
a
a
a
o
w
p
t
f
b
m
“
p
a
p
h
p
r
d
s
a
c
P
d
r
o
S
l
s
O
T
S
m
b
u
e
p
o
y
c
r
i
a
t
d
a
p
i
r
c
i
s
t
I
w
a
t
l
a
b
a
i
*
v
A
‡
§
W
Journal of the American College of Cardiology Vol. 54, No. 19, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2009.06.039EDITORIAL COMMENT
bstructive Sleep Apnea
Respiratory Syndrome With
rotean Cardiovascular Manifestations*
an Wilcox, MB, PHD,†‡
hristopher Semsarian, MB, BS, PHD†‡§
ydney and New South Wales, Australia
bstructive sleep apnea (OSA) presents with respiratory
ymptoms that include snoring, nocturnal choking, wit-
essed apneas, fragmented sleep, and symptoms of excessive
aytime tiredness and sleepiness. While sleepiness has been
ssociated with OSA, it only affects a minority of those with
SA in community-based studies (1,2). OSA occurs in all
acial groups and appears to be common, peaking in midlife,
ffecting up to 20% of men and 10% of women between the
ges of 39 to 65 years, the vast majority of whom remain
ndiagnosed (2). Despite presenting with respiratory symp-
oms, the most serious associations of OSA are cardiovas-
ular, including arrhythmias, hypertension, coronary dis-
ase, heart failure, and stroke (3–6).
See pages 1797 and 1805
Polysomnography (PSG) was used in early studies of
leep performed by Dement and Kleitman (7) in the 1950s
nd later came to be used extensively in research and clinical
ractice in sleep-disordered breathing. OSA was defined
mpirically using a combination of electroencephalogram
nd respiratory variables with the diagnosis defined by an
pnea-hypopnea index of 5 to 15 events/h. The use of PSG
s a diagnostic tool to measure and define OSA preceded
ur knowledge of how common heart disease was in patients
ith OSA, and its possible contribution to cardiovascular
athophysiology, by many years. A confounder of at-
empts to establish that OSA is an independent risk
actor for heart disease has been the strong association
etween it and other known risk factors, in particular the
etabolic “syndrome X.” In 1998 we proposed the term
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Sydney Medical School, University of Sydney, Sydney, Australia;
Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia; and thei
Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, New South
ales, Australia. Dr. Wilcox is a clinical consultant to ResMed Inc.syndrome Z” to draw attention to clinicians and their
atients to this relationship (8).
In this issue of the Journal, reports by Monahan et al. (9)
nd Eleid et al. (10) give important new insights into the
athophysiology of OSA and cardiovascular disease and
ave the potential to provide new therapeutic options for
atients with heart disease.
Early studies of heavy snorers, a marker for an increased
isk of having OSA, reported an increased risk of sudden
eath during the night (11). Since then, a series of retro-
pective studies have shown a relationship between OSA
nd tachyarrhythmias including atrial fibrillation (AF) and
omplex ventricular arrhythmias during single overnight
SGs, as well as an increased risk of subsequent sudden
eath, particularly at night (12,13). The magnitude of the
isk has been impressive, with an approximately 4-fold risk
f nocturnal AF and nonsustained ventricular tachycardia.
imilarly, a study of relatively young patients with normal
eft ventricular function and paroxysmal or persistent AF
howed that these patients were 3 times as likely to have
SA (apnea-hypopnea index 15) as control subjects (14).
hese findings contrast with studies such as the Euro Heart
urvey (15), which reported that OSA was a very uncom-
on trigger of symptomatic paroxysmal AF (0.3%).
Monahan et al. (9) examined the temporal relationship
etween breathing events and cardiac arrhythmias during
nattended home PSG studies performed at a follow-up
xamination of a cohort (n  2,816) of the original large
rospective multicenter Sleep Heart Health study. The
riginal study recruited 6,441 men and women age 40
ears with or without snoring, excluding patients already on
ontinuous positive airway pressure treatment (4,13). The
ecruitment process resulted in a study population that
ncluded predominantly snorers with relatively mild sleep
pnea. The purpose of the present study was to examine the
emporal relationship between respiratory events and car-
iac arrhythmias. In this population, the absolute risk of an
rrhythmia was low, as would be expected in a well
opulation with a short period of electrocardiogram record-
ng during sleep. Detection of arrhythmias using 24-h
ecordings is well known to be an insensitive method
ompared with longer duration recording methods such as
mplanted pacemakers, defibrillators, or loop recorders. The
tudy design would therefore tend to significantly underes-
imate the true frequency of AF in patients with OSA.
ndeed, the risk of developing AF and its consequences
ill clearly be affected by comorbidities such as obesity
nd other proinflammatory states, hypertension, left ven-
ricular hypertrophy, and heart failure. Despite these
imitations, the authors were able to demonstrate that an
rrhythmia was 18 times more likely to occur after a
reathing disturbance than normal sleep. These findings
dd significantly to what is already known about trigger-
ng of atrial and ventricular arrhythmias in heart disease
n general and OSA in particular.
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fforts are associated with atrial dilation, vagal stimulation
arly during apneas (16), and increased sympathetic nerve
ctivity later during the event, peaking with arousal from
leep and resumption of breathing (17,18). The increased
ympathetic nerve activity persists during the wakefulness.
his suggests that OSA may well be a more important
rigger of both “adrenergic” and “vagotonic” forms of AF
19) than was previously thought (15). These findings
uggest that AF plays a key role in the pathophysiology of
he increased risk of stroke and congestive heart failure in
atients with untreated OSA.
The notion that there is a link between OSA and clinical
utcomes in hypertrophic cardiomyopathy (HCM) is a
ascinating one, particularly if treatment of OSA results in
linical improvement and a reduced need for either phar-
acological or interventional therapy. OSA results in in-
reased sympathetic activity, impaired vagal activity, and
asoconstriction. It is conceivable that the pathophysiolog-
cal effects of OSA in HCM could include worsening
iastolic dysfunction, impaired hypertrophic remodeling,
riggering of both atrial and ventricular arrhythmias, as well
s an increase in left ventricular outflow tract obstruction,
ue both to the factors mentioned as well as increases in left
entricular filling pressures and a reduction in cardiac
utput. A recently reported study by Sengupta et al. (20) of
small cohort of 4 patients with HCM suggested treatment
f OSA using continuous positive airway pressure may
educe the need for more aggressive forms of treatment of
eft ventricular outflow tract obstruction, namely septal
eduction approaches.
The questions, however, remain; how prevalent is OSA
n patients with HCM, and in those where OSA is present,
oes treatment of OSA result in improved clinical outcomes
n HCM? The study by Eleid et al. (10) suggests a high
revalence of sleep-disordered breathing in 71% of HCM
atients tested. It is likely that this is an overestimate of the
rue prevalence, particularly given the population studied
as at a tertiary referral center where the most severe HCM
ases are likely to be referred, and the potential modifying
ole of hypertension (in 55%) in this HCM population. The
extbook definition of HCM states a disease characterized
y unexplained hypertrophy in the absence of loading
onditions such as hypertension. This casts some doubt on
hether a small proportion of patients in this cohort truly
ad HCM, or had HCM exacerbated by coexistent hyper-
ension, and whether genetic testing for the known sarco-
ere genes was performed in the patients with hyperten-
ion. Nevertheless, the presence of OSA in this HCM
opulation appears significant and supports an argument
hat perhaps all patients with HCM should be tested for
SA using simple investigations such as nocturnal oxime-
ry. In terms of the cardiovascular benefits of treatment of
SA in HCM patients, there are only a handful of reported
ases, although promising clinical outcomes are described
20). Clearly, to truly assess the prevalence of OSA inCM, and to determine whether treatment of OSA in
CM results in clinical improvement, larger, population-
ased, randomized, prospective studies are needed.
The cost and complexity of PSG has been an important
arrier to clinical and research studies in the past, but
ncreasingly, simpler, more cost effective, diagnostic tests are
eing developed. This process should enhance our ability to
esign and perform appropriately powered, randomized,
ontrolled studies of the consequences of OSA in patients
ith heart disease. Fortunately, a highly effective treatment
or OSA, nasal continuous positive airway pressure, was
escribed nearly 30 years ago by Sullivan et al. (21). Since
hen, alternative treatments, such as oral appliances, have
lso been developed and shown to be effective in addition
o sleeping position changes, weight loss, and other
easures (22).
Incorporating new paradigms of the importance of
SA in patients with heart disease into clinical practice
ill be critically dependent on cardiologists being more
losely involved in the diagnosis and, potentially, treat-
ent of OSA.
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